other dosage forms:
needed effects
ombitasvir
paritaprevir
ritonavir
unwanted side effects
medical attention
following side effects
taking
ombitasvir
paritaprevir
ritonavir
check
doctor
ombitasvir
paritaprevir
ritonavir side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
side effects
product in combination with ribavirin
placebo
fatigue
nausea
pruritus
other skin reactions
insomnia
asthenia
severity
patients
discontinued therapy
ribavirin
side effects
patients with genotype hepatitis c virus
hcv
infection
including
cirrhosis
using
product
common side effects
fatigue
nausea
therapy
side effects
patients
interrupted therapy
side effects
ribavirin dose
side effects
patients
patients with genotype hcv infection
using ombitasvir/paritaprevir/ritonavir
dasabuvir without ribavirin
pruritus
only side effect
patients
studies
placebo
ombitasvir/paritaprevir/ritonavir
dasabuvir
ribavirin
therapy
side effects
patients
interrupted therapy
side effects
patients
compensated cirrhosis
product with ribavirin
fatigue
skin reactions
dyspnea
weeks
weeks
most side effects
first weeks
therapy
side effects
patients
common side effects
product in combination with ribavirin in hcv/hiv
coinfected patients on stable antiretroviral therapy
fatigue
insomnia
nausea
headache
pruritus
cough
irritability
ocular icterus
common side effects
product in combination with ribavirin in post-liver transplant patients with recurrent hcv infection
fatigue
headache
cough
diarrhea
insomnia
asthenia
nausea
muscle spasms
rash
manufacturer product information for ribavirin
ribavirin-associated side effects
elevated total bilirubin
elevated alt
frequency
drug-related liver injury
jaundice
hyperbilirubinemiapostmarketing reports
hepatic decompensation
hepatic failure
grade
times
upper limit of normal
uln
grade
uln
total bilirubin elevations
patients
grade
uln
grade
uln
alt elevations
patients
post-baseline bilirubin elevations
uln
patients
product with ribavirin
using
product
increases
inhibition of oatpb/b
bilirubin transporters
paritaprevir
ribavirin-induced hemolysis
bilirubin elevations
therapy initiation
week of the study
ongoing therapy
elevated bilirubin
elevated serum alt
elevations in total bilirubin
uln
hcv/hiv
coinfected patients
product with ribavirin
time of bilirubin elevation
patients
using atazanavir
patients
ocular icterus
jaundice
hyperbilirubinemia
concurrent elevations of aminotransferases
hyperbilirubinemia
patients
post-baseline serum alt levels
times
upper limit of normal
uln
therapy
incidence
women
using
product
containing ethinyl estradiol
relevant alt elevations
women
using estrogens
ethinyl estradiol
estradiol
conjugated estrogens
hormone replacement therapy
alt elevations
first weeks of therapy
days
range
days
continued use
most alt elevations
drug-related liver injury
elevated alt
elevated bilirubin
cirrhosis
risk factor for elevated alt
hepatic decompensation
hepatic failure
including liver transplantation
fatal outcomes
patients
using ombitasvir/paritaprevir/ritonavir
dasabuvir
ribavirin
most patients with these severe outcomes
evidence of advanced/decompensated cirrhosis
starting therapy
cases
weeks
starting therapy
acute onset
rising
rising direct serum bilirubin levels without increases in alt
clinical signs/symptoms of hepatic decompensation
fatigue
asthenia
fatigue
hcv/hiv
coinfected patients
product with ribavirin
fatigue
asthenia
post-liver transplant patients
product with ribavirin
headache
hcv/hiv
coinfected patients
post-liver transplant patients
product with ribavirin
headache
dizziness
cough
hcv/hiv
coinfected patients
post-liver transplant patients
product with ribavirin
cough
dyspnea
diarrhea
nausea
vomiting
nausea
hcv/hiv
coinfected patients
product with ribavirin
diarrhea
nausea
post-liver transplant patients
product with ribavirin
pruritus
hcv/hiv
coinfected patients
product with ribavirin
rash
post-liver transplant patients
product with ribavirin
skin reactions
rash
erythema
eczema
maculopapular rash
macular rash
dermatitis
papular rash
skin exfoliation
pruritic rash
erythematous rash
generalized rash
allergic dermatitis
contact dermatitis
exfoliative rash
dermatitis
photosensitivity reaction
psoriasis
skin reaction
ulcer
urticaria
pruritus
pruritus
generalized pruritus
rash-related events
dry skin
muscle spasms
post-liver transplant patients
product with ribavirin
muscle spasms
insomnia
irritability
hcv/hiv
coinfected patients
product with ribavirin
insomnia
post-liver transplant patients
product with ribavirin
insomnia
irritability
disorder
ocular icterus
ocular icterus
hcv/hiv
coinfected patients
product with ribavirin
grade
g/dl
grade
g/dl
grade
g/dl
hemoglobin decreases
patients
phase trials
change from baseline in hemoglobin levels
g/dl in patients
product with ribavirin
g/dl in patients
product
hemoglobin level
therapy
week
further decreases through week
low hemoglobin values
therapy
baseline levels by weeks after therapy
patients
product with ribavirin
hemoglobin levels
g/dl during therapy
ribavirin dose
decreased hemoglobin levels
patients
blood transfusion
required erythropoietin
therapy
anemia in patient
patients
product
hemoglobin levels
g/dl
least post-baseline hemoglobin value
g/dl
hcv/hiv
coinfected patients
product with ribavirin
ribavirin dose
patients
patient
blood transfusion
erythropoietin
hcv/hiv
coinfected patients
product with ribavirin
cd
t-cell count
cells/mm
cells/mm by the end
weeks of therapy
baseline levels posttreatment
therapy
cd
t-cell counts
cells/mm
decrease in cd
patients
aids-related opportunistic infection
anemia
hemoglobin decreasedfrequency
decreased cd
t-cell counts
postmarketing reports
hypersensitivity reactions
including angioedema/tongue
lip
decreased appetite
side effects of viekira pak
fda
healthcare professional for medical advice
oral tablet
release
stomach pain
bloating of the abdomen
stomach
dark urine
light-colored stools
nausea and vomiting
yellow eyes
skin
blistering
peeling
loosening of the skin
chills
cough
diarrhea
itching
muscle pain
red skin lesions
purple center
red, irritated eyes
sore throat
sores
ulcers
white spots in the mouth
lips
unusual tiredness
weakness
itching skin
rash
lack
loss of strength
trouble sleeping